Adjuvant targeted therapy in early breast cancer

摘要: For this review, the authors appraised evidence for adjuvant trastuzumab therapy in early breast cancer. There was level 1 to support routine use of year conjunction with chemotherapy women human epidermal growth factor receptor 2 (HER-2)-positive The relative benefits concurrent versus sequential administration remained unclear; however permitted earliest possible intervention superiority. both lymph node-positive and highrisk node-negative patients, preliminary data suggested that all patient subgroups were eligible trials benefit equally from trastuzumab. Adjuvant associated a risk cardiotoxicity, long-term impact which remains largely unknown. Routine cardiac assessment considering left ventricular ejection fraction, age, prior history events is recommended along selection trastuzumab-based regimens minimize cardiotoxicity. Trastuzumab acquisition costs largest component treatment costs. Cancer 2009;115:1154–68. V C 2009 American Society.